Downregulation or loss of TGF-β receptors was observed in about 30% of cases of prostate cancer compared with normal prostate tissues while expressions of TGFBR1 and TGFBR2 were lower in metastatic compared with primary tumors [234]. Here, TGFBR2 is linked to prostate carcinoma.